Proof-point cadence: the last promised marker just landed, and the next one is already on the clock
The model's full reasoning — Q2 2021 call → NOWe need to determine if management presents a live, checkable sequence of proof points with both a marker just delivered and a next marker named and near. Let's examine the transcript. Key elements: The company discusses Q2 results, Firdapse sales, business development, R&D programs. They mention progress on long-acting Firdapse formulation, MuSK-MG, HNPP, patents, litigation, etc. Specifically, they mention: "We are currently evaluating and conducting due diligence on what we believe are several very exciting opportunities to expand our portfolio... hoping to complete one or more company or product acquisitions before the end of this year." That's a future aspiration, not a just-delivered marker. They mention the DyDo licensing agreement completed in Q2, which contributed revenue. That is a concrete step completed. But is it a "marker just delivered" on a path? They had announced it last quarter, so it's a recent completion. However, the question asks for a specific operational step that was set out to accomplish and just completed. The DyDo agreement is a licensing deal, not necessarily a checkpoint on a forward path like a product launch or approval. But it is a concrete step. They also mention the patent issuance: "in April, the USPTO allowed patent #11,060,128 for Firdapse and this patent issued in July 13, 2021." That is a concrete milestone. They also mention the denial of motion to dismiss in patent litigation. But are these presented as part of a sequence with a next marker? They mention the long-acting formulation: "an additional PK study will be conducted later this year." That is a next step with timing. But is the just-delivered marker? They had a PK study completed in Q4 2020, and now they are refining formulations. That is ongoing, not a just-completed marker in this quarter. They mention MuSK-MG: they are planning to convene an expert panel to decide whether to continue. That is a next step but not with specific timing. They mention HNPP: they decided not to proceed with company-sponsored study, but are in discussions for investigator-sponsored study. That is a change. The question asks: Does management present the company's progress as a live, checkable sequence of proof points with both a marker just delivered and a next marker named and near? The essence is one phenomenon: moving through an execution sequence in real time.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | Q3 2023 | 2023-11-04 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HIW | Highwoods Properties, Inc. | Q4 2022 | 2023-02-08 | B |
| TCBI | Texas Capital Bancshares, Inc. | Q2 2021 | 2021-07-21 | F |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| INSM | Insmed Incorporated | Q4 2017 | 2018-02-23 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
XOM · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES Management presents a live, checkable sequence of proof points. In Neil Chapman's remarks, he explicitly notes that the Coral Floating LNG project is "progressing on schedule" and that "fabrication of the hull is expected to start in the third quarter of this year" — a concrete, near-term operational checkpoint 3–4 months away. Immediately prior, he states that "earlier this month, we announced that the development plan for the first phase has been submitted," treating that submission as the just-completed marker on the same path. He anchors the next step as "targeting final investment decision in 2019" with 2024 first LNG, presented as scheduled and already in motion rather than aspirational. This forms one coherent posture: the company is executing a verifiable execution sequence on the Mozambique LNG opportunity, with the development-plan submission just cleared and FID locked for 2019. Other examples (Baytown ethane cracker operations begun yesterday; 50 new Permian wells brought to sales in the quarter) exist, but the Mozambique LNG thread satisfies both required elements on a single forward path. No other elements (financial beats, routine maintenance, or analyst questions) are used to construct the sequence.
MKC · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing the Frank's and French's integration as a completed checkpoint ("With the acquisition and integration complete"), then immediately naming and anchoring the next concrete steps on the same path — such as launching the first dedicated mustard campaign in the U.S. (kicked off this week during the call) and 2018 U.S. national TV advertising for Frank's in the second half — as scheduled, in-motion activities that will drive further growth. This is presented as one coherent execution sequence rather than isolated results. Other elements like distribution gains and summer grilling promotions are tied directly to this progression. No routine or vague items qualify; 2018 advertising and marketing acceleration are explicitly tied to the post-integration trajectory.
CMPS · Q3 2023 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing progress as a live execution sequence: the open-label PTSD Phase II study has just reached full recruitment (a concrete checkpoint passed), and they explicitly name the next marker — top-line readout this year — as the immediate follow-on step already in motion and scheduled within the coming months. This is presented as part of the same forward trajectory they are tracking, alongside the TRD Phase III where site initiations (3/4 of COMP005) are described as continuing to advance toward the summer 2024 readout.